Loading patent…
AssigneeIdera Pharmaceuticals, Inc.
InventorsSudhir Agrawal, Fu-Gang Zhu, Ekambar Kandimalla
Estimating the term…
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
A method for therapeutically treating a patient having airway inflammation, inflammatory disorders, allergy, or asthma, such method comprising administering to the patient an immunomer, wherein the immunomer has the sequence of 5′-TCRTCRTTG-X-GTTRCTRCT-5′, wherein R is arabinoguanosine and X is glycerol linker.
A method for preventing airway inflammation, inflammatory disorders, allergy, or asthma in a patient, such method comprising administering to the patient an immunomer, wherein the immunomer has the sequence of 5′-TCRTCRTTG-X-GTTRCTRCT-5′, wherein R is arabinoguanosine and X is glycerol linker.
Dependencies are inferred from the claim text.